X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

New Advanced DualBeam Increases Productivity and Expands Ease-of-Use

Content Team by Content Team
8th August 2019
in Manufacturing, News
Helios 5 DualBeam microscope

Thermo Fisher Scientific unveiled its most advanced focused ion beam scanning electron microscope (FIB-SEM) for materials science researchers and engineers, the Thermo Scientific Helios 5 DualBeam microscope. The microscope allows users of all experience levels to generate higher-quality results than previous generations and is the first-ever commercially available DualBeam capable of unattended, fully automated, in situ preparation of location-specific ultra-thin samples for a wide range of materials.

“Scientists and engineers in academic institutions and research and development labs continue to push the boundaries in developing safer, stronger, more durable materials to help many industries advance their products,” said Mike Shafer, president, materials and structural analysis, Thermo Fisher Scientific. “The vastly improved ease-of-use and productivity enhancements in our new Helios 5 DualBeam microscope will help our materials science customers deliver the results they need to stay on the leading edge of discovery.”

By creating high-quality samples for atomic scale analysis in a transmission electron microscope, the Helios 5 DualBeam can assist materials science researchers working with multi-scale, multi-modal correlative workflows for the characterization of complex materials and provide 3D visualization at the nanometer scale. For engineers developing high strength steels, the Helios 5 can be used to build lighter, safer and less expensive cars. For researchers developing materials used in additive manufacturing, it can be used to build more complex parts for aircraft engines that offer better fuel efficiency.

Thermo Fisher designed advancements for the new Helios 5 to ensure the system’s operation is optimal for both manual and automated workflows. Those improvements include:

Greater ease-of-use: Improved accessibility for users of all experience levels reduces training requirements and enables consistent results on a wide variety of advanced applications. Operator training may be reduced from months to days and is designed to enable all operators to achieve consistent, repeatable results on a wide variety of advanced applications.

Increased productivity: Advanced automation capabilities, increased robustness and stability enhancements significantly increase the sample preparation throughput compared to prior models by allowing unattended and even overnight operation.

Improved time to results: The Helios 5 now includes FLASH, a new concept of tuning the image. With conventional microscopes, each time an operator needs to acquire an image, the microscope has to be carefully tuned by iterative adjustments to components in the microscope. A simple hand gesture across the Helios 5 screen will activate FLASH, which automatically adjusts the parameters needed to acquire a new image, improving throughput, data quality, and significantly simplifying the acquisition of high quality, high resolution images.

First shipments of the Helios 5 for materials science customers will take place this year. For more information, please visit thermofisher.com/helios5.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Previous Post

GSK grants exclusive technology license for clinical stage Ebola vaccines to Sabin Vaccine Institute

Next Post

GlycoMimetics Reports Top-line Results From Pfizers Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Next Post
Pfizers Phase 3 Clinical Trial

GlycoMimetics Reports Top-line Results From Pfizers Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In